Impact of Dose to Cardiac Substructures on Survival in Patients With Esophageal Cancer Treated With Radiotherapy or Chemoradiotherapy (SATIATION)

Launched by UNIVERSITY HOSPITAL, BREST · Aug 16, 2023

Keywords

ClinConnect Summary

The SATIATION clinical trial is studying how the amount of radiation that reaches different parts of the heart affects the survival of patients with esophageal cancer who are receiving treatment. Patients with esophageal cancer often receive radiotherapy (radiation treatment) or chemoradiotherapy (a combination of radiation and chemotherapy). While we know that radiation can affect the heart, this trial aims to find out if focusing on specific areas of the heart can help improve patient outcomes.

To be eligible for this study, participants must be at least 18 years old and have been diagnosed with localized or locally advanced esophageal cancer that is being treated with radiotherapy or chemoradiotherapy. They should have received a minimum dose of radiation (at least 50 Gy) and must not have undergone surgery for their cancer. Participants can expect to be monitored throughout the trial to understand the effects of their treatment better. This study is currently looking for volunteers, and it is crucial for potential participants to be aware that those with other significant health issues or who refuse to participate will not be included in the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Histologically or cytologically proven esophageal cancer
• • Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy
• • Tumor dose ≥ 50 Gy
• • Non-opposition of living patients formulated
• • Patient affiliated to a social security scheme
• Exclusion Criteria:
• • Age \< 18 years
• • Patient treated with upfront surgery
• • Tumor dose \< 50 Gy
• • Other concomitant neoplasia
• • Metastatic patient
• • Refusal to participate
• • Patient under legal protection (guardianship, curatorship, etc...)